A Phase 2 Multicenter, Open-Label, Parallel Cohort Expansion Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-Mesenchymal-epithelial Transition Factor (c-MET) Dysregulation

Inclusion Criteria: 1. Male or female ≥ 18 years of age or designated age of majority according to the regulatory authorities, whichever is higher. 2. Eastern Cooperative Oncology Group (ECOG) performance status (PS), 0 or 1. 3. Have a life expectancy of at least 3 months. 4. Diagnosis: 1. must have histologically or cytologically confirmed NSCLC, advanced, recurrent, or metastatic, 2. For Cohort 1: MET exon 14 skipping suspected by local or central biomarker assessment. \[local testing is accepted for eligibility; all patients will have confirmation by central laboratory, but this res…